Baxter International Inc.

▲ Bull Case

• ◆Novum IQ clears + North Cove volume recovers simultaneously: The two largest revenue headwinds resolve in FY2026–FY2027; pent-up pump refresh demand releases in H1 2027; IV volumes normalize to pre-Helene baseline; combined EBITDA recovery of $300–400M over two years drives stock to $28–32.
• ◆CEO Hider executes operational turnaround with disciplined capex and margin recovery: New CEO (operational background from ATS Corp) improves manufacturing efficiency; gross margins recover from current ~35% toward historical ~40%; adj EBITDA margin returns to 15%+ by FY2028; ROIC crosses WACC for first time since Hillrom.
• ◆North Cove operating leverage is non-linear: Each percentage point of volume recovery at the largest US IV plant drops through at ~65–70% incremental contribution margin — a small volume increase creates disproportionate EBITDA upside; hospital conservation reversal of even 5–8% adds $100–200M EBITDA.

▼ Bear Case

• ◆Novum IQ extends into FY2027–FY2028, moat begins to erode: Hospital procurement teams locked out of Novum IQ must use B. Braun or ICU Medical pumps for multi-year contracts; once the installed base shifts, the bundled switching cost moat (pump + IV fluids + sets) is permanently weakened; HST segment permanently smaller.
• ◆IV conservation behavior is partially permanent: Recent clinical research supports reducing IV fluid volumes in certain patient populations (SMART trial, SPLIT trial); hospital efficiency programs built around lower IV utilization are structural, not situational; MPT segment revenue ceiling is permanently lower than pre-Helene.
• ◆FY2026 guidance miss triggers leverage concern: A single-quarter adverse event pushes adj EPS below $1.60; EBITDA misses $1.05B guidance; Net Debt/EBITDA rises to 9x+; credit downgrade risk; stock falls to $8–10 on leverage concern narrative.

“The debate is not about whether Baxter has a moat — it does. The debate is whether the balance sheet can support the company long enough for the moat to re-express itself. Bulls argue $17.30 prices in near-distress; the moat is real (40–45% US IV market share, pump switching costs, surgical sealant leadership); once leverage normalizes at 2.5–3.0x, intrinsic value is $28–35/share. Bears counter that the leverage is structural, not temporary; adjusted EBITDA metrics add back $300–400M of real costs; GAAP EBITDA of $673M vs. $9.7B gross debt = 14.4x; Novum IQ has no timeline; and management track record is poor (3/4 guidance misses). The resolution will come from the FY2026 full-year results (February 2027) — the first year where all adverse events are nominally contained.”

• ◆Q2 2026 earnings (August 2026): Adj EPS ≥$0.50 run-rate toward $1.85 FY2026 confirms base case; below $0.40 signals bear case building
• ◆Novum IQ FDA hold resolution (H2 2026 at earliest): Clearance = +15–20% stock reaction; extension = -15–25%
• ◆Permanent CFO appointment (Q2–Q3 2026): Governance signal and lender confidence indicator
• ◆IV volume normalization data (Q3 2026): MPT segment volume trajectory vs. prior year reveals whether conservation behavior is structural
• ◆FY2026 full-year results (February 2027): First full year of continuing ops with all catalysts measured simultaneously

• ◆Novum IQ hold extended 18–24+ months (MEDIUM-HIGH probability, HIGH impact): Moat erosion begins as hospital installed base migrates to competitors permanently
• ◆FY2026 adj EPS miss >10% (MEDIUM-HIGH probability, HIGH impact): Credit narrative resets; stock falls to $10–12
• ◆CFO vacancy creates lender confidence issue (MEDIUM probability, HIGH impact): Debt refinancing on worse terms; ongoing governance concern
• ◆IV conservation permanently lower by 10–15% (MEDIUM probability, MEDIUM-HIGH impact): MPT segment revenue ceiling structurally reset lower
• ◆Additional adverse event — quality, regulatory (MEDIUM probability, HIGH impact): 'One more thing' narrative destroys management credibility
• ◆Dilutive equity raise (LOW-MEDIUM probability, HIGH impact): Dilution at $10–14/share permanently impairs return of capital to current holders